Background Following Australia’s landmark 2023 decision to approve psilocybin and MDMA for clinical use, psychedelic-assisted therapy (PAT) is beginning to emerge within regulated mental health settings. This study investigates psychologists’ views on the relevance of psychedelic therapists’ lived-living experience (LLE) with psychedelics. While discussion around LLE is growing, little is known...
Abstract Introduction This study explores the attitudes of psychologists towards psychedelics and psychedelic‐assisted therapy (PAT) following the world‐first regulatory changes in 2023 in Australia which permitted psilocybin and 3,4‐methylenedioxy‐methamphetamine (MDMA) to be used in clinical services. Methods A purposive sample of 20 Australian psychologists was recruited using snowball...